Format

Send to

Choose Destination
Exp Gerontol. 2015 Aug;68:19-25. doi: 10.1016/j.exger.2014.10.012. Epub 2014 Oct 28.

Clinical strategies and animal models for developing senolytic agents.

Author information

1
Mayo Clinic Robert and Arlene Kogod Center on Aging, 200 First Street, S.W., Rochester, MN 55905, United States. Electronic address: Kirkland.james@mayo.edu.
2
Mayo Clinic Robert and Arlene Kogod Center on Aging, 200 First Street, S.W., Rochester, MN 55905, United States.

Abstract

Aging is associated with increasing predisposition to multiple chronic diseases. One fundamental aging process that is often operative at sites of the pathology underlying chronic age-related diseases is cellular senescence. Small molecule senolytic agents are being developed. For successful drug development: 1) appropriate animal models of human age-related diseases need to be devised. 2) Models have to be made in which it can be proven that beneficial phenotypic effects are actually caused through clearing senescent cells by putative senolytic agents, as opposed to "off-target" effects of these agents on non-senescent cells. 3) Models are needed to test efficacy of drugs and to uncover potential side effects of senolytic agents. Development of the optimal animal models and clinical trial paradigms for senolytic agents warrants an intensive effort, since senolytic agents, if successful in delaying, preventing, alleviating, or reversing age-related diseases as a group would be transformative.

KEYWORDS:

Cellular senescence; Healthspan; Senescence-associated secretory phenotype; Senolytic

PMID:
25446976
PMCID:
PMC4412760
DOI:
10.1016/j.exger.2014.10.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center